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Background: Tuberculosis (TB) presents globally a significant health problem and health care workers (HCW) are at
increased risk of contracting TB infection. There is no diagnostic gold standard for latent TB infection (LTBI), but
both blood based interferon-gamma release assays (IGRA) and the tuberculin skin test (TST) are used. According to
the national guidelines, HCW who have been exposed for TB should be screened and offered preventive anti-TB
chemotherapy, but the role of IGRA in HCW screening is still unclear.
Methods: A total of 387 HCW working in clinical and laboratory departments in three major hospitals in the
Western region of Norway with possible exposure to TB were included in a cross-sectional study. The HCW were
asked for risk factors for TB and tested with TST and the QuantiFERONWTB Gold In-Tube test (QFT). A logistic
regression model analyzed the associations between risk factors for TB and positive QFT or TST.
Results: A total of 13 (3.4%) demonstrated a persistent positive QFT, whereas 214 (55.3%) had a positive TST
(≥ 6 mm) and 53 (13.7%) a TST ≥ 15 mm. Only ten (4.7%) of the HCW with a positive TST were QFT positive. Origin
from a TB-endemic country was the only risk factor associated with a positive QFT (OR 14.13, 95% CI 1.37 - 145.38,
p = 0.026), whereas there was no significant association between risk factors for TB and TST≥ 15 mm. The five HCW
with an initial positive QFT that retested negative all had low interferon-gamma (IFN-γ) responses below 0.70 IU/ml
when first tested.
Conclusions: We demonstrate a low prevalence of LTBI in HCW working in hospitals with TB patients in our region.
The “IGRA-only” seems like a desirable screening strategy despite its limitations in serial testing, due to the high
numbers of discordant TST positive/IGRA negative results in HCW, probably caused by BCG vaccination or boosting
due to repetitive TST testing. Thus, guidelines for TB screening in HCW should be updated in order to secure
accurate diagnosis of LTBI and offer proper treatment and follow-up.
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Tuberculosis (TB) presents globally a significant health
problem and healthcare workers (HCW) are at increased
risk of contracting latent TB infection (LTBI) and
develop active TB [1,2]. The prevalence of TB infection
and disease are highest among HCW in low/middle
income countries [1]. The overall incidence of TB in
Norway is 7/100.000 and of the approximately 350 new
TB cases annually 80-90% are imported infections from
TB-endemic countries [3]. According to the national
guidelines those exposed for TB, including HCW, should
be screened for TB infection and preventive anti-TB
chemotherapy should be considered [4].
The tuberculin skin test (TST) has high sensitivity, but
low specificity, especially in Bacillus Calmette-Guérin
(BCG)-vaccinated individuals, because of cross-reactivity
to non-tubercular mycobacterias (NTM) or due to
booster-effect caused by repetitive testing [5]. This has
resulted in long-term medical follow-up for many HCW
with positive TST. There is no diagnostic gold standard
test for LTBI, but blood based interferon-gamma release
assays (IGRA) offer better specificity (98–100%) and at
least as good sensitivity (70–97%) as the TST since they
are unaffected by previous BCG vaccination and most
NTM [2,6-9]. These assays, commercially available as
QuantiFERONWTB Gold In-Tube (QFT) and T-SPOT.
TBW measure in-vitro IFN-γ production by T-cells stimu-
lated with the M. tuberculosis-specific antigens ESAT-6,
CFP-10 and TB7.7. The tests have already been incorpo-
rated into national guidelines [10-13] and in Norway the
QFT is recommended since 2007 as the test of choice
following TST in a two-step approach [14]. Still, the role
of IGRA in HCW screening is unclear [15].
Studies from TB low-endemic countries generally find
a low prevalence of LTBI in HCW defined by IGRA
[15,16,18-27]. A high proportion of discordant TST
positive/IGRA negative results have been reported in
HCW, especially in countries with high coverage of BCG
vaccination [15,16,23,27-29]. In Norway a limited num-
ber of studies of the performance of IGRA in various
populations have been published [23,30-33], but no
study has focused on the routine screening of HCW. We
have previously shown in a cohort with a predominance
of immigrants that although one third tested QFT posi-
tive, in HCW, a subgroup of the study participants, only
10% had a positive QFT test [32].
We have performed a cross-sectional study amo-
ngst HCW in three major hospitals in the Western
region of Norway to study the prevalence of QFT
positivity in HCW working in hospital departments
with possible risk of TB infection, identify possible
risk factors for LTBI in our hospitals and investigate
the performance of the QFT test in routine testing
of HCW.Methods
Study participants
HCW working in out-patient TB clinics and wards at
the departments of Pulmonary medicine and Infectious
medicine or in the laboratories at the departments of
Microbiology and Pathology in three major hospitals in
the Western region of Norway were included in the
study in the period from September 2008 to September
2009. All HCW had possible contacts with patients with
diagnosed or suspected infectious TB, infected biological
material or TB cultures as part of clinical work or
diagnostic procedures and consisted of medical doctors,
nurses, laboratory staff and administrative personnel.
The study participants with a positive QFT were
followed according to clinical practice with clinical and
radiological examination to rule out active TB. Treat-
ment of LTBI for three months was offered in accord-
ance with the Norwegian recommendations [4]. The
following variables were registered using a standardized
questionnaire: age, sex, workplace, occupation, country of
origin, year of immigration, previous TB, stay (>2 weeks)
or work in a TB endemic country, occupational exposure
to TB in the actual hospital or outside the hospital
(included working in hospitals in TB-endemic coun-
tries), prior TST and BCG vaccination, also assessed
through inspection for scars. A TST (0.1 ml tuberculin
PPD RT23 2 TU, SSI, Copenhagen, DK) was performed
after blood was collected for QFT to avoid the possibility
of boosting and read after 72 hours [4]. In some subjects
no TST was performed due to earlier strong reactions or
previous TB infection [34].
Inclusion in the study was voluntary and written in-
formed consent was given from all the study participants
before inclusion in the study. The study was approved
by the Regional Ethics Committee for Medical Research
(REK-vest) and the Norwegian Data Inspectorate.
QuantiFERON TB-gold in-tube assay
Blood was drawn from all HCW at their respective hos-
pitals and analysed with the QuantiFERONW TB-Gold
In-tube assay (QFT), (Cellestis/Qiagen) at the laboratory
for Infectious diseases at Haukeland University hospital.
All HCW with a positive or inconclusive QFT test were
offered retesting. The HCW with negative first test
were not retested. The blood samples were treated as
recommended by the manufacturer. Briefly, one ml of
whole blood was sampled in each of the three QFT
tubes containing either TB specific antigen (ESAT-6,
CFP-10 and TB7.7), no antigen (negative control) or
mitogen antigen (positive control) and the IFN-γ con-
centrations (IU/ml) in plasma was measured by an
ELISA reader and calculated by the ‘QFT-TB-analysis
Software’. An IFN-γ ≥ 0.35 IU/ml (TB antigens minus
negative control) was considered a positive test.
Table 1 Characteristics of study participants (n = 387)
Characteristics No (%)
Age 1) 36 23-64
Sex
Male 61 15.8
Female 326 84.2
Origin
Norway 357 92.2
TB low-endemic country 15 3.9
TB high-endemic country 15 3.9
Work place
Infectious Medicine 160 41.3
Pulmonary Medicine 123 31.8
Microbiology 80 20.7
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Statistical analysis was performed using SPSS 20 and
the graphics was done by Matlab 2010a. Data are
presented as median values with range. Univariate as-
sessment of risk factors for positive QFT and TST ≥
15 mm was done by Chi square test and t-test as
appropriate.
The associations between QFT and TST as depen-
dent variables and age, sex, country of origin, stay
in TB endemic country and TB exposure as pre-
dictors were analyzed by a logistic regression model. We
considered a fully adjusted multivariate model con-
taining all predictors as well as an univariate model for
each predictor. We selected 15 mm as cut-off to
dichotomize TST. The general significance level was set
to 0.05.Pathology 24 6.2
Profession
Nurse 222 57.4
Physician 60 15.5
Laboratory staff 99 25.6
Administration 6 1.6
Work TB endemic country 2) 59 15.2
Stay TB endemic country 2) 288 74.4
Exposure to TB at work 3)
Patients 239 61.8
Laboratory 85 22.0
Exposure to TB outside work 50 12.9
BCG vaccinated 379 97.9
BCG scar 358 92.5
Previous TB 3 0.8
1)Median (range). Definitions: TB = Tuberculosis. 2)The three longest visits were
registered. 3)The three longest contacts were registered.Results
Study population
A total of 387 HCW working in the clinical departments
diagnosing and treating TB patients or in the laborator-
ies handling possible TB infected biological samples were
included in the study (Table 1). The majority of the
study participants were female (84.2%) and the median
age was 36. Most of them were ethnically Norwegians
(92.2%) and only 15 (3.9%) had migrated from TB high-
endemic regions, predominately from Asia. The majority
of the HCW were nurses (57.4%), 15.5% were physicians,
25.6% were laboratory staff and 1.6% were administra-
tion staff. A history of BCG vaccination was reported in
97.9% and the time since BCG-vaccination was median
21 years. Most of the foreign-born were vaccinated as
infants or young children, whereas the Norwegians were
vaccinated at the age of fourteen according to the
Norwegian national vaccination program [4]. Three
HCW (0.8%), all from TB low-endemic countries, had
previously been treated for active TB disease (8, 13 and
29 years back). A total of 74.4% of the HCW reported
stay in a TB-endemic country, most for shorter time-
periods and only 34% stayed for a minimum of three
months, whereas 59 (15.2%) HCW had been working
in a TB-endemic country, but only 21 of them
worked for a period of three months or more. The
median time since the last work period was five years
(range 0-33). A total of 61.8% of the HCW reported
known exposure to an infectious TB patient at their
workplace and 22% reported contact with TB infected
biological material. The majority of the HCW reported
use of infection control equipment during contact with
TB patients or infectious material (82.4% and 83.2%,
respectively). Known exposure to TB outside work,
including at foreign hospitals, was reported in 50
(12.9%) HCW.Characteristics of health care workers with a positive
QuantiFERON-TB test
A positive QFT result was observed in 18 HCW when
first tested (median 0.76 IU/ml, range 0.39-7.9 IU/ml)
(Table 2). These HCW, except two refusing to repeat the
test, were retested twice or three times. Thus, after
retesting 13 (3.4%) of all the HCW had a persistent posi-
tive QFT, indicating LTBI. Two HCW tested positive the
first time (0.40-0.76 IU/ml), then negative the second
test (0.30 IU/ml), whereas both reverted to positive
(0.49-0.93 IU/ml) when tested for the third time and
were concluded as positive. The additional five HCW
with a positive initial QFT that retested negative all had
low initial responses (0.39-0.66 IU/ml). In two other
HCW the QFT was initially indeterminate, but negative
when retested.
Table 2 Characteristics of HCW with positive or indeterminate QuantiFERON-TB
HCW Age Sex 1. QFT (IU/ml) Origin Occupation BCG TST ≥ 6 2. QFT (IU/ml)
1 22 F 4.51 Norway Laboratory no yes 9.51
2 35 F 0.57 Norway Laboratory yes yes −0.05
3 26 F 0.66 Norway Laboratory yes yes −0.01
4 41 F 0.40 Asia Laboratory yes yes 0.491
5 34 M 0.76 Norway Laboratory yes no 0.931
6 32 F IND Norway Laboratory yes yes 0.05
7 24 F 1.60 Norway Nurse yes yes 1.09
8 59 F 0.47 Norway Nurse yes 2 0.49
9 39 F 0.39 Norway Secretary yes yes −0.01
10 44 F 0.40 W. Europe Physician yes yes 2
11 46 M 1.09 Norway Physician yes yes 1.36
12 29 M 0.46 Norway Physician yes no −0.14
13 54 M 2.31 Norway Physician yes yes 2.66
14 44 M 1.66 N. America Physician no yes 2
15 28 M IND Norway Nurse yes yes neg
16 25 F 7.90 Africa Nurse yes no pos3
17 60 F 5.85 Asia Nurse yes yes 4.15
18 60 F 0.68 Norway Assistant yes yes neg3
19 65 F 1.31 Norway Nurse yes yes 2.17
20 33 M 5.51 Norway Physician yes yes >10
1Third QFT, second test 0.30 UI/ml in both HCW 4 and 5. 2No test was performed. 3No value was given.
QFT = QuantiFERON-TB. IND = indeterminate.
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tive QFT were as follows; the HCW worked in different
hospitals in different departments. Five were nurses, five
medical doctors and three laboratory staff. One HCW had
been diagnosed with active TB 29 years back, but had only
received treatment for four months. It is of note that the
two others with previous active TB were QFT negative.
Ten QFT positive HCW were born in western TB low-
endemic countries, the majority in Norway and three had
origin from TB-endemic regions. Eleven of the QFT
positive HCW were BCG vaccinated with visible scars.
Eight HCW reported stay, but only two reported working
in a TB-endemic region. All QFT positive HCW reported
known exposure to TB during work at the hospital in
Norway. Ten HCW reported contact with an infectious TBTable 3 Multivariate analysis of risk factors associated with a
Univariate (N = 13)
Characteristics OR (95% CI)
Female 3.54 (1.12, 11.21)
Age 1.04 (0.99, 1.09)
Origin 9.05 (2.20, 37.16)
Stay in TB endemic country 0.74 (0.22, 2.45)
OR; odds ratio; CI; confidence interval; OR per standard-deviation increase for contin
Norway, 2) other TB low- endemic countries, 3) TB endemic countries; Stay in TB en
Exposure to TB was too unbalanced to produce definite confidence intervals and thpatient, eight HCW at two or more occasions and six had
performed or assisted during bronchoscopy. Nine of these
had used recommended infection control equipment at
regular basis. Three HCW had been in contact with TB
infected biological material during diagnostic handling or
procedures and had for most of the occasions used
infection control equipment. Seven HCW had also been in
contact with TB-patients outside the hospital. In the univar-
iate logistic regression analysis female and country of origin
were significant associated with a positive QFT, whereas in
the multivariate analysis only country of origin remained
significant (Table 3). Clinical and radiological examination
did not show any signs of active TB in any of the HCW.
They were offered preventive TB therapy after medical
evaluation, but only one was treated.positive QFT
Multivariate (N = 13)
P-value OR (95% CI) P-value
.031 2.59 (0.76, 8.86) .131
.141 1.03 (0.98, 1.08) .259
.002 14.13 (1.37, 145.38) .026
.681 0.80 (0.31, 2.04) .632
uous variables Age; Origin; country of birth, divided into three groups, 1)
demic country; stayed and/or worked in TB endemic country (>2 weeks).
erefore not reported.
Table 4 QuantiFERON-TB results in HCW for various TST
reactions
Induration
(mm)
TST (n = 387) QFT (n = 13)
n (%) n (% of TST group)
≥ 6 214 (55.3) 10 (4.7)
0-5 154 (39.8) 2 (1.3)
6-10 85 (22.0) 4 (4.7)
11-14 76 (19.6) 4 (5.3)
≥ 15 53 (13.7) 2 (3.8)
No TST1 19 (4.9) 1 (5.3)
TST = tuberculin skin test. QFT = QuantiFERON-TB.
1)Not tested due to previous strong response or previous active TB.
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results in health care workers
A total of 214 (55.3%) demonstrated a positive TST
(≥ 6 mm) and 13.7% had even TST ≥ 15 mm (Table 4).
In 19 (4.9%) a TST was not performed due to earlier
strong reactions or previous active TB. In the multivari-
ate analysis there was no significant association between
risk factors for TB infection and TST ≥ 15 mm (Table 5).
Only 4.7% of the HCW with a positive TST ≥ 6 mm
were QFT positive and there was a wide range of TST
reactions seen in the QFT positive group (Table 4). Only
two of the 53 (3.8%) HCW with TST ≥ 15 mm demon-
strated a positive QFT and none one of the two HCW
with previously strong TST responses > 25 mm were
QFT positive. In contrast, two of the TST negative
HCW (1.3%) were QFT positive, one with origin from a
TB endemic country and the other had been exposed for
TB at work in the laboratory (Table 2; HCW 5 and 16,
respectively). The association between TST and QFT for
the various age groups is shown in Figure 1.
Discussion
We present a cross sectional study on routine IGRA testing
of HCW working in three major hospitals in the Western
region of Norway, a TB low-endemic country. We find that
only 3.4% of the HCW tested positive with QFT in contrast
to 55.3% with TST, indicating low level of LTBI in HCWTable 5 Multivariate analysis of risk factors associated with a
Univariate (n = 384
Characteristics OR (95% CI)
Female 0.34 (0.08, 1.47)
Age 1.01 (0.98, 1.05)
Origin 1.66 (0.36, 7.69)
Stay in TB endemic country 0.86 (0.38, 1.92)
Exposure to TB 0.79 (0.34, 1.84)
OR; odds ratio; CI; confidence interval; OR per standard-deviation increase for contin
Norway, 2) other TB low- endemic countries, 3) TB endemic countries; Stay in TB en
Exposure to TB; exposed to TB at work, either in direct contact with patients or in aworking at Norwegian hospitals. This is in support of a
previous Norwegian contact investigation study that also
found a frequency of 3% of LTBI among HCW by the
T-SPOT.TB test [23] and a Danish study from hospital
medical wards where only 1% of the HCW had a positive
QFT [16]. In contrast, in a study from Russia, a TB high-
endemic country, 47% of the HCW in the TB department
were IGRA positive [17]. We did not find any effect of age
on the QFT results. In the study by Nienhaus et al,
however, IGRA results among HCW depended greatly on
age and country with a QFT positivity of 25% in Germany,
45% in Portugal and 33% in France in the age group over
55 years [26]. In a recent review from Zwerling et al. the
pooled prevalence of positive IGRA using either test was
significantly lower than for a positive TST among HCW in
low TB incidence settings, and IGRA showed good correl-
ation with occupational risk factors for TB exposure [29].
The 13 HCW with a persistent positive QFT were
equally distributed between the three hospitals and
between nurses, medical doctors and laboratory staff
and the majority was born in Norway. All HCW
reported known exposure to TB at work, but had used
infection control equipment during patient care and
diagnostic procedures. Seven HCW reported additional
possible environmental exposure to TB. Further, four of
the HCW had either origin from and/or reported work-
ing in TB high-endemic regions. It is likely that these
were infected abroad since country of origin was the
only risk factor significantly associated with a positive
QFT test in the multivariate analysis. One HCW had
been diagnosed with active TB several years back illus-
trating that IGRAs could stay positive long after treated
infection [32]. From 2005 a total of 47 HCW with
TB infection, of whom 14 developed active TB, have
been reported in Norway (personal communication,
The Norwegian Institute of Public Health). However, 25
were born outside Norway possibly implying that TB ex-
posure had occurred abroad. Based on our results we can-
not conclude for sure, but altogether this indicates a low
risk of contracting TB and a good infectious control at
Norwegian hospitals.TST ≥ 15 mm
) Multivariate (n = 53)
P-value OR (95% CI) P-value
.148 0.27 (0.06, 1.21) .088
.413 1.02 (0.98, 1.05) .382
.519 1.16 (0.19, 7.16) .871
.705 0.42 (0.12, 1.55) .193
.588 0.79 (0.33, 1.90) .598
uous variables Age; Origin; country of birth, divided into three groups, 1)
demic country; stayed and/or worked in TB endemic country (>2 weeks);
laboratory.
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Figure 1 Relationship between age, tuberculin skin test and QFT. The red triangles show the study participants with a positive QFT (n = 12).
The circles show the study participants with a negative QFT (n = 355). One QFT positive was not included since no TST was performed.
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IGRA could replace the TST when screening HCW for
TB in routine practice or contact investigations due to the
improved specificity [15,18,26-28]. This is especially
relevant in countries like Norway with high coverage of
BCG vaccination and discordant TST positive/IGRA
negative results. In a Canadian study LTBI prevalence
among HCW measured by the TST was low and the most
common discordant test results were TST negative/QFT
positive [35]. In contrast, we observed that a total of 33%
of the HCW had TST > 10 mm, 13.7% had TST ≥ 15 mm
with a frequency of only 4% QFT positivity and even
HCW with the highest TST values > 25 mm were QFT
negative. This might represent false negative QFT, but
there was no association between known TB risk factors
and TST ≥ 15 mm. BCG vaccination at the age of fourteen
was performed according to the Norwegian national
vaccination program from 1947 to 2009 and explains why
98% of all the HCW in our cohort were vaccinated. Thus,
the discrepancy it most likely explained by false positive
TST due to high BCG vaccination coverage or booster
effects after repeatedly TST testing in the hospitals. With
over half of the HCW in our study demonstrating a posi-
tive TST, which we believe is representative for HCW
working at Norwegian hospitals, it is obvious the TST in
our setting generally is of little use. Instead, IGRA offer
better specificity and thereby lower prevalence of positive
tests and fewer HCW who require X-rays, further clinical
follow-up or LTBI treatment. Still, medical follow-up ofHCW with strong TST reactions and risk factors for TB
reactivation might be warranted since there is no diagnos-
tic gold standard for LTBI.
There is concern about IGRA reproducibility, defining
the optimum cut-off values for positive tests which most
accurately distinguish new TB infection from random
variation as well as defining the right interpretation of
discordant TST and IGRA in serial screening [29,36,37].
In our study, the HCW with initial positive QFT that
retested negative all had low initial IFN-γ responses
below 0.70 IU/ml. Poor reproducibility of the assay is a
more likely explanation than true reversions since
the tests were performed within short periods. Such
fluctuations in IGRA findings were also demonstrated in
a study where HCW in contact with TB patients were
tested monthly [38]. When an increase in QFT cut-off
from < 0.35 to ≥ 0.70 IU/ml was applied inconsistent
IGRA results were reduced from 52% to 27% and
consistency in QFT results was associated with baseline
IFN-γ levels. A recent review also concludes that
subjects with baseline results around the diagnostic
threshold are more likely to show inconsistent results on
retesting [36]. Also in our cohort there was a tendency
to higher IFN-γ levels in those with consistent positive
QFT. Thus, a borderline zone from 0.20-0.70 IU/ml has
been suggested in the routine screening of HCW
with retesting before preventive chemotherapy is rec-
ommended [36]. Longitudinal research is therefore re-
quested to inform guidelines on IGRA serial testing.
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their introduction recommended the two new IGRAs for
screening of LTBI [11]. Others, including the Norwegian
guidelines, have in general been more cautious and
recommended a two-step approach with an initial TST
[14]. The European guidelines conclude that IGRA may
be used as part of the overall risk assessment to diagnose
LTBI and identify individuals for preventive treatment
[10]. In the updated guidelines from the USA the advan-
tages and disadvantages of the various tests are discussed
[39]. When choosing test one must consider the accur-
acy of the test in the specific risk groups as well as
populations. The guidelines also conclude that due to
the high negative predictive value, progression to active
TB in healthy immune competent individuals with
negative IGRA is very unlikely.
According to Norwegian guidelines HCW who has
worked or stayed in a TB endemic country or are
included in contact investigations should be screened for
TB infection in a two-step approach with an initial TST
before IGRA [14]. Many hospitals have also performed
regular routine TST in HCW with risk for TB infection
at their workplace. Our study demonstrating a high
frequency of discordant TST positive/IGRA negative
results indicates that the National guidelines should be
updated and an “IGRA-only strategy” considered for
HCW. Use of IGRA in this population is expected to
increase diagnostic specificity and improve acceptance of
treatment for LTBI. The higher per-test cost of IGRAs
may be compensated for by lower post-screening costs
(medical follow-up, chest x-rays and chemoprevention).
A recent review of cost-effectiveness of IGRA concludes
that in four studies, the “two-step strategy” and in two
studies the “IGRA-only strategy” was most cost-effective
[40]. A recent British study concludes that IGRA can be
an institutional cost saving and result in higher compli-
ance rates [41]. There is growing evidence in support of
the use of IGRA in screening risk groups such as HCW.
However, one must be aware of the uncertainty of IGRA
during serial-testing with yet undefined proper cut-off
levels and possible low-level false-positive IGRA results
that will lead to unnecessary follow-up of low-risk HCW.
The limitations of our study are the small number of
IGRA positive to draw strong conclusions on the overall
prevalence of TB infection in HWC in Norway, the risk
factors for TB infection and the effects of serial testing.
In addition it is not possible to show the frequency
of converters since no repetitive testing of the QFT
negative were performed.
Conclusions
We find in this cross sectional study that only 3.4% of
HCW were QFT positive in contrast to 55.3% TST posi-
tive indicating a low level of LTBI among HCW workingat hospitals in Western Norway. The only risk factor asso-
ciated with a positive QFT was origin from a TB-endemic
country implying a low risk for contracting TB infection at
Norwegian hospitals. The “IGRA-only” seems like a desir-
able strategy, despite its limitations, due to the high
number of false positive TST probably caused by BCG
vaccination and repetitive TST testing. Thus, there is a
need for an update of Norwegian guidelines for TB
screening in HCW in order to get more accurate diagnosis
of LTBI and offer proper treatment and follow-up.
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